semaglutide 2.0 Novo Nordisk and Hims & Hers Partner to Expand Access FDA approves once-a-week diabetes shot

Phase 3 TRIUMPH-4 Results: The Latest Data (December 2025) The first Phase 3 results for Retatrutide came from the TRIUMPH-4 trial, announced by Eli Lilly on December 11, 2025

The standard formulation is designed to deliver precise amounts of the active ingredient, allowing healthcare providers to prescribe it with confidence based on established clinical guidelines

MOTS-c: 10mg research peptide

For patients first prescribed an ADM in September 2024, 68.99% filled a GLP-1 RA within 60 days

The breast milk data showing sub-threshold RID levels provides a degree of reassurance that other GLP-1 medications cannot yet match